Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer. (Q54115748)
Jump to navigation
Jump to search
scientific article published on 27 February 2018
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer. |
scientific article published on 27 February 2018 |
Statements
Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer (English)
Amir Noeparast
Sylvia De Brakeleer
Ulrike De Ridder
Erik Teugels
Jacques De Grève
27 February 2018
1 reference